CTLA4 and neoplasm: Experimental studies on rats suggest the efficacy of a DNA vaccine targeting CTLA-4 and PD-1, while other studies focus on developing mRNA vaccines for CCA targeting tumor antigens (CD247, TRRAP, FCGR1A) [57,58].